Payment overview · 2025
General Payments
$852.17
48 reported records · 10 companies
Healthcare provider profile · identity verified
Matthew Harold Bucher, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FRANKFORT, KY · NPI 1295939791
Verified facts
What the public records show
CMS Open Payments records show Matthew Harold Bucher, M.D. received $852.17 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $340.53 | 40.0% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.54 | 17.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.14 | 16.3% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.86 | 8.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.76 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.21 | 3.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.92 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.06 | 2.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.18 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.97 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $852.17 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $204.41 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $204.41 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.14 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.12 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.05 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $126.05 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.86 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.86 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $11.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 191 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
191 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 775 | 215 |
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 161 |
| Lisinopril | Lisinopril | 490 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 135 |
| Omeprazole | Omeprazole | 445 | 109 |
| Gabapentin | Gabapentin | 432 | 83 |
| Metformin Hcl Er | Metformin Hcl | 371 | 97 |
| Famotidine | Famotidine | 357 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 104 |
| Losartan Potassium | Losartan Potassium | 330 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 314 | 123 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 313 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 306 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 269 | 61 |
| Trazodone Hcl | Trazodone Hcl | 265 | 77 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 260 | 69 |
| Montelukast Sodium | Montelukast Sodium | 254 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 56 |
| Buspirone Hcl | Buspirone Hcl | 226 | 48 |
| Tramadol Hcl | Tramadol Hcl | 226 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 56 |
| Sertraline Hcl | Sertraline Hcl | 219 | 56 |
| Ezetimibe | Ezetimibe | 210 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 195 | 48 |
| Carvedilol | Carvedilol | 191 | 49 |
| Ozempic | Semaglutide | 191 | 49 |
| Furosemide | Furosemide | 189 | 57 |
| Baclofen | Baclofen | 184 | 64 |
| Bupropion Xl | Bupropion Hcl | 181 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 42 |
| Valsartan | Valsartan | 158 | 47 |
| Metformin Hcl | Metformin Hcl | 147 | 39 |
| Jardiance | Empagliflozin | 138 | 33 |
| Spironolactone | Spironolactone | 137 | 38 |
| Finasteride | Finasteride | 132 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 38 |
| Eliquis | Apixaban | 125 | 38 |
| Allopurinol | Allopurinol | 118 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Celecoxib | Celecoxib | 113 | 28 |
| Alendronate Sodium | Alendronate Sodium | 111 | 32 |
| Ipratropium Bromide | Ipratropium Bromide | 104 | 39 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 102 | 26 |
| Glimepiride | Glimepiride | 101 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 20 |
| Potassium Chloride | Potassium Chloride | 94 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 19 |
| Donepezil Hcl | Donepezil Hcl | 87 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 21 |
| Clonazepam | Clonazepam | 78 | 13 |
| Mirtazapine | Mirtazapine | 78 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 17 |
| Synthroid | Levothyroxine Sodium | 77 | 20 |
| Pregabalin | Pregabalin | 75 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 18 |
| Fluconazole | Fluconazole | 71 | 26 |
| Alprazolam | Alprazolam | 70 | 20 |
| Xarelto | Rivaroxaban | 70 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | 23 |
| Glipizide Er | Glipizide | 68 | 20 |
| Lansoprazole | Lansoprazole | 66 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 66 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Simvastatin | Simvastatin | 64 | 20 |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Nabumetone | Nabumetone | 58 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 54 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 33 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | 12 |
| Azelastine Hcl | Azelastine Hcl | 53 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 11 |
| Chlorthalidone | Chlorthalidone | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 13 |
| Myrbetriq | Mirabegron | 48 | 13 |
| Ondansetron Odt | Ondansetron | 47 | 14 |
| Meloxicam | Meloxicam | 46 | 19 |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Methocarbamol | Methocarbamol | 44 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 44 | 15 |
| Promethazine Hcl | Promethazine Hcl | 43 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Nystatin | Nystatin | 39 | 18 |
| Cefuroxime | Cefuroxime Axetil | 38 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 15 |
| Mupirocin | Mupirocin | 36 | 26 |
| Farxiga | Dapagliflozin Propanediol | 35 | 12 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 13 |
| Cefdinir | Cefdinir | 33 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 15 |
| Glipizide | Glipizide | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Prolia | Denosumab | 19 | 11 |
| Topiramate | Topiramate | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Torsemide | Torsemide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $852.17 · 48 records | ABBVIE INC. | AIRSUPRA, CONTRAVE, FARXIGA, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VIVITROL, VRAYLAR, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error